Celcuity Inc. (NASDAQ: CELC)

Celcuity Inc., a clinical-stage biotechnology company (NASDAQ: CELC), operates in the biotechnology industry, specifically focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's main business activities revolve around the research, development, and clinical testing of novel therapeutic candidates, with a particular focus on gedatolisib, a compound that targets the phosphatidylinositol-3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) pathways. Celcuity's operations span across various countries, including the United States, where its headquarters are located, and other regions where its clinical trials take place.

Celcuity generates revenue through the development and clinical testing of gedatolisib, its lead therapeutic candidate. The company's primary product is gedatolisib, a potent, well-tolerated, small molecule reversible inhibitor that selectively targets all Class I isoforms of PI3K and the two mTOR sub-complexes, mTORC1 and mTORC2. Gedatolisib has shown promising results in preclinical and clinical studies, demonstrating a unique mechanism of action and pharmacokinetic properties that differentiate it from other approved and investigational therapies targeting PI3K or mTOR. The company's primary customer base consists of clinical trial participants, pharmaceutical partners, and potential future patients, should gedatolisib receive regulatory approval. Celcuity's competitive advantage lies in the unique mechanism of action of gedatolisib, which targets both PI3K and mTOR pathways, and its potential to treat various solid tumor indications.

Within the biotechnology industry, Celcuity competes with several other companies developing targeted therapies for cancer treatment. Some of its key competitors include companies specializing in diagnostic testing, such as Foundation Medicine, Caris Life Sciences, NeoGenomics, LabCorp, Quest, Nanostring, Paradigm, Biocept, Exosome Diagnostics, Guardant Health, Roche Diagnostics, Qiagen, Myriad, and Genomic Health. Celcuity's success depends on its ability to protect its intellectual property, maintain proprietary protection for its product candidates, manufacturing and process discoveries, and other know-how. The company plans to protect its proprietary positions using a variety of methods, including protecting current U.S. and foreign patents related to proprietary technology, inventions, and improvements, and prosecuting additional U.S. and foreign patents that it determines are important to the development and implementation of its business.

Celcuity's product portfolio includes its lead therapeutic candidate, gedatolisib, which is currently being evaluated in multiple clinical trials for the treatment of breast and prostate cancer. In the breast cancer program, Celcuity focuses on the treatment of patients with HR+/HER2- advanced breast cancer who have progressed on CDK4/6 therapy. Gedatolisib has been granted Fast Track and Breakthrough Therapy designations by the FDA for the treatment of patients with HR+/HER2- metastatic breast cancer after progression on CDK4/6 therapy. In a Phase 1b study, gedatolisib was evaluated in combination with palbociclib and fulvestrant in patients with HR+/HER2- advanced breast cancer, demonstrating a 64% objective response rate (ORR) and a 92% clinical benefit rate (CBR). The company is currently conducting a Phase 3, open-label, randomized clinical trial, VIKTORIA-1, to evaluate the efficacy and safety of gedatolisib in combination with fulvestrant with or without palbociclib in adults with HR+/HER2- advanced breast cancer whose disease has progressed after prior CDK4/6 therapy.

In the prostate cancer program, Celcuity is focused on the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Preclinical studies have demonstrated a potential association between the PAM pathway and androgen receptor (AR) signaling in prostate cancer cells developing resistance to androgen deprivation therapy (ADT). Gedatolisib has shown promising results in preclinical studies, inhibiting the PAM pathway in combination with an AR inhibitor. The company is currently conducting a Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with mCRPC. The trial is expected to enroll approximately 100 patients.